Loss of junctophilin-3 contributes to huntington disease-like 2 pathogenesis

Annals of Neurology

Volumn 71, Issue 2, 2012, Pages 245-257

  Seixas, Ana I ^a,b   Holmes, Susan E ^a   Takeshima, Hiroshi ^c   Pavlovich, Amira ^a,d   Sachs, Nancy ^a,e   Pruitt, Jennifer L ^a   Silveira, Isabel ^b   Ross, Christopher A ^a   Margolis, Russell L ^a   Rudnicki, Dobrila D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c KYOTO UNIVERSITY   (Japan)

^d Princeton University   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; JUNCTOPHILIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GENE LOCUS; GENE LOSS; HEMIZYGOSITY; HUNTINGTON DISEASE LIKE SYNDROME; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

AGE OF ONSET; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NEUROPSYCHOLOGICAL TESTS; OLIGONUCLEOTIDES, ANTISENSE; PREFRONTAL CORTEX; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84857520653     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22598     Document Type: Article

References (47)

1. Margolis RL, O'Hearn E, Rosenblatt A, et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol 2001; 50: 373-380. (Pubitemid 32848740)
2. Walker RH, Jankovic J, O'Hearn E, et al. Phenotypic features of Huntington's disease-like 2. Mov Disord 2003; 18: 1527-1530. (Pubitemid 38035378)
3. Wild EJ, Tabrizi SJ,. Huntington's disease phenocopy syndromes. Curr Opin Neurol 2007; 20: 681-687. (Pubitemid 350085010)
4. Magazi DS, Krause A, Bonev V, et al. Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J 2008; 98: 200-203. (Pubitemid 351516346)
5. Rudnicki DD, Pletnikova O, Vonsattel JP, et al. A comparison of Huntington disease and Huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol 2008; 67: 366-374. (Pubitemid 351507491)
6. Holmes SE, O'Hearn E, Rosenblatt A, et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet 2001; 29: 377-378. (Pubitemid 34326684)
7. Margolis RL, Holmes SE, Rosenblatt A, et al. Huntington's disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004; 56: 670-674. (Pubitemid 39540747)
8. Takeshima H, Komazaki S, Nishi M, et al. Junctophilins: a novel family of junctional membrane complex proteins. Mol Cell 2000; 6: 11-22.
9. Nishi M, Mizushima A, Nakagawara K, et al. Characterization of human junctophilin subtype genes. Biochem Biophys Res Commun 2000; 273: 920-927. (Pubitemid 30481055)
10. Nishi M, Sakagami H, Komazaki S, et al. Coexpression of junctophilin type 3 and type 4 in brain. Brain Res Mol Brain Res 2003; 118: 102-110. (Pubitemid 37238992)
11. Yamazaki D, Yamazaki T, Takeshima H,. New molecular components supporting ryanodine receptor-mediated Ca(2+) release: roles of junctophilin and TRIC channel in embryonic cardiomyocytes. Pharmacol Ther 2009; 121: 265-272.
12. Uehara A, Yasukochi M, Imanaga I, et al. Store-operated Ca2+ entry uncoupled with ryanodine receptor and junctional membrane complex in heart muscle cells. Cell Calcium 2002; 31: 89-96. (Pubitemid 34552448)
13. Matsushita Y, Furukawa T, Kasanuki H, et al. Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy. J Hum Genet 2007; 52: 543-548. (Pubitemid 46835828)
14. Nishi M, Hashimoto K, Kuriyama K, et al. Motor discoordination in mutant mice lacking junctophilin type 3. Biochem Biophys Res Commun 2002; 292: 318-324. (Pubitemid 34694266)
15. Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007; 61: 272-282. (Pubitemid 46557351)
16. Sambrook J, Russell DW,. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
17. Cho DH, Thienes CP, Mahoney SE, et al. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 2005; 20: 483-489. (Pubitemid 41572304)
18. Youssoufian H,. Immunoaffinity purification of antibodies against GST fusion proteins. Biotechniques 1998; 24: 198-200, 202.
19. Harlow E, Lane D,. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988.
20. Huttner WB, Schiebler W, Greengard P, et al. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol 1983; 96: 1374-1388. (Pubitemid 13029640)
21. Hazeki N, Tukamoto T, Goto J, et al. Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. Biochem Biophys Res Commun 2000; 277: 386-393.
22. Dyer RB, McMurray CT,. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat Genet 2001; 29: 270-278. (Pubitemid 33096451)
23. Reese MG,. Application of a time-delay neural network to promoter annotation in the Drosophila melanogaster genome. Comput Chem 2001; 26: 51-56. (Pubitemid 33034559)
24. Davuluri RV, Grosse I, Zhang MQ,. Computational identification of promoters and first exons in the human genome. Nat Genet 2001; 29: 412-417. (Pubitemid 34326691)
25. Wilburn B, Rudnicki DD, Zhao J, et al. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron 2011; 70: 427-440.
26. Li SH, Schilling G, Young WS III, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993; 11: 985-993. (Pubitemid 23347482)
27. Brooks E, Arrasate M, Cheung K, et al. Using antibodies to analyze polyglutamine stretches. Methods Mol Biol 2004; 277: 103-128.
28. Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18: 164-167. (Pubitemid 28082465)
29. Dorsman JC, Pepers B, Langenberg D, et al. Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells. Hum Mol Genet 2002; 11: 1487-1496. (Pubitemid 34679249)
30. Nasrallah IM, Minarcik JC, Golden JA,. A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J Cell Biol 2004; 167: 411-416. (Pubitemid 39489049)
31. Crawley JN,. What's wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. 2nd ed. Hoboken, NJ: Wiley-Liss, 2007.
32. Moseley ML, Zu T, Ikeda Y, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006; 38: 758-769. (Pubitemid 43980596)
33. Batra R, Charizanis K, Swanson MS,. Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum Mol Genet 2010; 19: R77-R82.
34. Ross CA, Wood JD, Schilling G, et al. Polyglutamine pathogenesis. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1005-1011. (Pubitemid 29477961)
35. Chung DW, Rudnicki DD, Yu L, et al. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet 2011; 20: 3467-3477.
36. Takahashi J, Fukuda T, Tanaka J, et al. Neuronal intranuclear hyaline inclusion disease with polyglutamine-immunoreactive inclusions. Acta Neuropathol 2000; 99: 589-594. (Pubitemid 30201325)
37. Ishikawa K, Owada K, Ishida K, et al. Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells. Neurology 2001; 56: 1753-1756. (Pubitemid 32574581)
38. Bennett MJ, Huey-Tubman KE, Herr AB, et al. A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A 2002; 99: 11634-11639. (Pubitemid 34994451)
39. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995; 378: 403-406.
40. van Roon-Mom WM, Reid SJ, Jones AL, et al. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain Res Mol Brain Res 2002; 109: 1-10. (Pubitemid 36078369)
41. Perez MK, Paulson HL, Pendse SJ, et al. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 1998; 143: 1457-1470. (Pubitemid 29006496)
42. Uchihara T, Fujigasaki H, Koyano S, et al. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias triple-labeling immunofluorescence study. Acta Neuropathol 2001; 102: 149-152. (Pubitemid 32771662)
43. Donoviel DB, Hadjantonakis AK, Ikeda M, et al. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev 1999; 13: 2801-2810.
44. Ikegami S, Harada A, Hirokawa N,. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett 2000; 279: 129-132. (Pubitemid 30069810)
45. Schmitt I, Linden M, Khazneh H, et al. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 2007; 362: 734-739. (Pubitemid 47368155)
46. Moriguchi S, Nishi M, Komazaki S, et al. Functional uncoupling between Ca2+ release and afterhyperpolarization in mutant hippocampal neurons lacking junctophilins. Proc Natl Acad Sci U S A 2006; 103: 10811-10816. (Pubitemid 44078058)
47. Ikeda A, Miyazaki T, Kakizawa S, et al. Abnormal features in mutant cerebellar Purkinje cells lacking junctophilins. Biochem Biophys Res Commun 2007; 363: 835-839. (Pubitemid 47513705)